Efficacy and toxicity of Herceptin in treating 56 patients with Her-2 positive breast cancer

Objetive: To observe the efficacy and toxicity of Herceptin in treating 56 patients with Her-2 positive breast cancer.Methods: 56 patients with Her-2 positive breast cancer were randomly divided into 3 groups.There were single-agent group,combined-group and control group.Single-agent group(n=18),Herceptin was given 4 mg/kg,then 2 mg/kg,for 1 year;Combined-group(n=20),Docetaxel was given 75 mg/m2 every 3 week,and Herceptin was given 4 mg/kg.The patients accepted 4 times of chemotherapy in total.After the first chemotherapy,Herceptin was keep on therapy every month with the dose of 4 mg/kg,and it was used in 4 times,too;Control group(n=20),patients were given the general chemotherapy.Results: In the two groups of the therapy with Herceptin,objective remission rate of group 1 and group 2 was 50.0% and 83.3% respectively,and the TTP was 5.8 months and 10.4 months respectively.The clinical curative effects of the two groups using Herceptin were better than that of the control group,which had remarkable difference(P0.05) Conclusion: Both Herceptin in single agent and combined with the chemotherapy drug are effective in the treatment of Her-2 positive advanced breast cancer,and Herceptin combined chemotherapy could obtain more significant effect in treating breat cancer.